Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY Study
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The primary objective of this study was to determine whether the National Cholesterol Education Program Step II (NCEP-II) diet or supplementation with docosahexaenoic acid (DHA) with the diet, affects endothelial function in children with familial hypercholesterolemia (FH) or the phenotype of familial combined hyperlipidemia (FCH). As secondary endpoints, the influence of diet and DHA supplementation on lipid profiles as well as biomarkers for oxidative stress and inflammation, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, were all evaluated. METHODS: In a double-blind, placebo-controlled, randomized, crossover study design, 20 children (ages 9-19 years) with FH (n = 12) and FCH (n = 8) received nutritional counseling based on the National Cholesterol Education Program Step II (NCEP-II) and food guide pyramid dietary guidelines for 6 weeks. They were then randomly assigned to supplementation with docosahexaenoic acid (DHA 1.2 g/d) or placebo for 6 weeks, followed by a washout phase of 6 weeks and crossover phase of 6 weeks while continuing the NCEP-II diet. Endothelium-dependent flow-mediated dilation (FMD) of the brachial artery was determined by high-resolution ultrasound. Plasma levels of total cholesterol, triglycerides and lipoprotein classes (LDL, HDL, VLDL) were measured by ultracentrifugation and enzymatic methods, plasma F2 isoprostanes by gas chromatography/mass spectrometry, urinary 8-OH-2' deoxyguanosine by liquid chromatography, high sensitivity C-reactive protein by immunonephelometry and ADMA by liquid chromatography. RESULTS: FMD increased significantly after DHA supplementation compared to baseline (p < 0.001), diet alone (p < 0.002), placebo (p < 0.012) and washout (p < 0.001) phases of the study without affecting biomarkers for oxidative stress, inflammation or ADMA. DHA supplementation was associated with increased levels of total cholesterol (p < 0.01), LDL- and HDL cholesterol concentrations (p < 0.001) compared to the NCEP-II diet. CONCLUSION: This study demonstrates that DHA supplementation restores endothelial-dependent FMD in hyperlipidemic children. The endothelium may thus be a therapeutic target for DHA. This is consistent with a hypothesis of increasing NO bioavailability, with the potential for preventing the progression of early coronary heart disease in high-risk children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771
Omega-3 polyunsaturated fatty acids and their health benefits
Shahidi, F., & Ambigaipalan, P. (2018) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-111317-095850 · Cited by 1,390
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J. (2006) · Circulation · doi:10.1161/circulationaha.106.179568 · Cited by 707
A Systemic Review of the Roles of n-3 Fatty Acids in Health and Disease
Riediger, N. D., Othman, R. A., Suh, M., & Moghadasian, M. H. (2009) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.12.022 · Cited by 695
Urbina, E. M., Williams, R. V., Alpert, B. S., Collins, R. T., Daniels, S. R., Hayman, L., Jacobson, M., Mahoney, L., Mietus-Snyder, M., Rocchini, A., et al. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.192639 · Cited by 641
Self-citationSerhan, C. N., Dalli, J., Colas, R. A., Winkler, J. W., & Chiang, N. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.006 · Cited by 492
Serhan, C. N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S. P., & Petasis, N. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1848 · Cited by 455
McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Hayman, L. L., & Daniels, S. R. (2007) · Circulation · doi:10.1161/circulationaha.107.181946 · Cited by 418
EFSA Panel on Dietetic Products, N. A. A. (. (2012) · EFSA Journal · doi:10.2903/j.efsa.2012.2815 · Cited by 370
Skulas-Ray, A. C., Kris-Etherton, P. M., Harris, W. S., Vanden Heuvel, J. P., Wagner, P. R., & West, S. G. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.003871 · Cited by 280
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263
“The mean baseline LDL-C was,200 mg/dL in all studies except 1, inwhich the average baseline LDL-Cwas 213 mg/dL.(35)”
BackgroundThe differential effects of EPA and DHA on cardiovascular risk factors
Cottin, S. C., Sanders, T. A., & Hall, W. L. (2011) · Proceedings of the Nutrition Society · doi:10.1017/s0029665111000061 · Cited by 247
“8 g/d; 3 months) increased endothelium-dependent forearm blood flow response in untreated hypertriglyceridaemic males (108) , whereas DHA alone (1.2 g/d; 6 weeks) improved endothelium-dependent FMD in hyperlipidaemic children receiving nutritional counselling (109) .”
InfluentialHill, A. M., Buckley, J. D., Murphy, K. J., & Howe, P. R. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.5.1267 · Cited by 237
“Elevated histamine concentrations and diminished DAO activities have been shown for various inflammatory and neoplastic diseases such as Crohn disease (17), ulcerative colitis (67), allergic enteropathy (39), food allergy (33, 68, 69), and colorectal neoplasmas (24).”
BackgroundResultInfluentialThe clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
Backes, J., Anzalone, D., Hilleman, D., & Catini, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0286-4 · Cited by 195
Arterburn, L. M., Oken, H. A., Hoffman, J. P., Bailey‐Hall, E., Chung, G., Rom, D., Hamersley, J., & McCarthy, D. (2007) · Lipids · doi:10.1007/s11745-007-3098-5 · Cited by 135
Nauroth, J. M., Liu, Y. C., Van Elswyk, M., Bell, R., Hall, E. B., Chung, G., & Arterburn, L. M. (2010) · Lipids · doi:10.1007/s11745-010-3406-3 · Cited by 89
Engler, M. M., Engler, M. B., Malloy, M. J., Paul, S. M., Kulkarni, K. R., & Mietus-Snyder, M. L. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.12.014 · Cited by 76
Self-citationRyan, A. S., Keske, M. A., Hoffman, J. P., & Nelson, E. B. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fe2be · Cited by 72
“By increasing nitric oxide bioavailability, DHA may have the potential to delay the early onset of coronary heart disease in hyperlipidemic children.(10) The effects of a fish-enriched diet or dietary supplements of fish oil or algal-DHA on platelet aggregation and homeostatic factors were studied in healthy men.”
BackgroundOh, P. C., Koh, K. K., Sakuma, I., Lim, S., Lee, Y., Lee, S., Lee, K., Han, S. H., & Shin, E. K. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.075 · Cited by 54
“Several studies reported that omega-3 fatty acids improve flowmediated arterial dilation [26–28].”
Background
Metadata
- Authors
- Engler, M. M., Engler, M. B., Malloy, M., Chiu, E., Besio, D., Paul, S., Stuehlinger, M., Morrow, J., Ridker, P., Rifai, N., & Mietus-Snyder, M.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2004-12-01
- Volume
- 42
- Issue
- 12
- Pages
- 672-679
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2036725388
- Cited by
- 151
- References
- 0
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.